A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop

Virology

Volumn 418, Issue 2, 2011, Pages 123-132

  Ringe, Rajesh ^a   Sharma, Deepak ^a   Zolla Pazner, Susan ^b   Phogat, Sanjay ^c   Risbud, Arun ^a   Thakar, Madhuri ^a   Paranjape, Ramesh ^a   Bhattacharya, Jayanta ^a  

^a NATIONAL AIDS RESEARCH INSTITUTE   (India)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

C4 domain; CD4bs; Clade C; Envelope; HIV 1; Neutralizing antibody; Recent infection; V3 loop

Indexed keywords

AMINO ACID; CD4 ANTIGEN; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; ISOLEUCINE; METHIONINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN B12; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBODY BLOOD LEVEL; ARTICLE; BINDING SITE; CHIMERA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION REGULATION, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV-1; METHIONINE; MOLECULAR SEQUENCE DATA; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052100386     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.07.015     Document Type: Article

References (86)

1. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455(7213):613-619.
2. Bell C.H., Pantophlet R., Schiefner A., Cavacini L.A., Stanfield R.L., Burton D.R., Wilson I.A. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J. Mol. Biol. 2008, 375(4):969-978.
3. Bhattacharya J., Peters P.J., Clapham P.R. CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. AIDS 2003, 17(Suppl 4):S35-S43.
4. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78:13232-13252.
5. Blay W.M., Gnanakaran S., Foley B., Doria-Rose N.A., Korber B.T., Haigwood N.L. Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques. J. Virol. 2006, 80(2):999-1014.
6. Blish C.A., Nguyen M.A., Overbaugh J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med. 2008, 5(1):e9.
7. Bunnik E.M., Pisas L., van Nuenen A.C., Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 2008, 82(16):7932-7941.
8. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
9. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., Kelly J.W., Rudd P.M., Dwek R.A., Katinger H., Burton D.R., Wilson I.A. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300:2065-2071.
10. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., Burton D.R., Wilson I.A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22(2):163-173.
11. Carrow E.W., Vujcic L.K., Glass W.L., Seamon K.B., Rastogi S.C., Hendry R.M., Boulos R., Nzila N., Quinnan G.V. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. AIDS Res. Hum. Retroviruses 1991, 7(10):831-838.
12. Chesebro B., Wehrly K., Nishio J., Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 1992, 66(11):6547-6554.
13. Clapham P.R., Weber J.N., Whitby D., McIntosh K., Dalgleish A.G., Maddon P.J., Deen K.C., Sweet R.W., Weiss R.A. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 1989, 337(6205):368-370.
14. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., Allen S., Hunter E. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004, 303(5666):2019-2022.
15. Doria-Rose N.A., Klein R.M., Daniels M.G., O'Dell S., Nason M., Lapedes A., Bhattacharya T., Migueles S.A., Wyatt R.T., Korber B.T., Mascola J.R., Connors M. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 2010, 84(3):1631-1636.
16. Duenas-Decamp M.J., Clapham P.R. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12. J. Virol. 2010, 84(18):9608-9612.
17. Duenas-Decamp M.J., Peters P., Burton D., Clapham P.R. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J. Virol. 2008, 82(12):5807-5814.
18. Duenas-Decamp M.J., Peters P.J., Burton D., Clapham P.R. Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. J. Virol. 2009, 83(6):2575-2583.
19. Fauci A.S., Johnston M.I., Dieffenbach C.W., Burton D.R., Hammer S.M., Hoxie J.A., Martin M., Overbaugh J., Watkins D.I., Mahmoud A., Greene W.C. HIV vaccine research: the way forward. Science 2008, 321(5888):530-532.
20. Gorny M.K., Wang X.H., Williams C., Volsky B., Revesz K., Witover B., Burda S., Urbanski M., Nyambi P., Krachmarov C., Pinter A., Zolla-Pazner S., Nadas A. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol. Immunol. 2009, 46(5):917-926.
21. Gray E.S., Moore P.L., Bibollet-Ruche F., Li H., Decker J.M., Meyers T., Shaw G.M., Morris L. 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J. Virol. 2008, 82(5):2367-2375.
22. Gray E.S., Moore P.L., Choge I.A., Decker J.M., Bibollet-Ruche F., Li H., Leseka N., Treurnicht F., Mlisana K., Shaw G.M., Karim S.S., Williamson C., Morris L. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 2007, 81(12):6187-6196.
23. Gray E.S., Moore P.L., Pantophlet R.A., Morris L. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J. Virol. 2007, 81(19):10769-10776.
24. Hart T.K., Kirsh R., Ellens H., Sweet R.W., Lambert D.M., Petteway S.R., Leary J., Bugelski P.J. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(6):2189-2193.
25. Hartley O., Klasse P.J., Sattentau Q.J., Moore J.P. V3: HIV's switch-hitter. AIDS Res. Hum. Retroviruses 2005, 21(2):171-189.
26. Hioe C.E., Wrin T., Seaman M.S., Yu X., Wood B., Self S., Williams C., Gorny M.K., Zolla-Pazner S. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One 2010, 5(4):e10254.
27. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310(5750):1025-1028.
28. Jiang X., Burke V., Totrov M., Williams C., Cardozo T., Gorny M.K., Zolla-Pazner S., Kong X.P. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat. Struct. Mol. Biol. 2010, 17(8):955-961.
29. Kinsey N.E., Anderson M.G., Unangst T.J., Joag S.V., Narayan O., Zink M.C., Clements J.E. Antigenic variation of SIV: mutations in V4 alter the neutralization profile. Virology 1996, 221(1):14-21.
30. Kolchinsky P., Kiprilov E., Bartley P., Rubinstein R., Sodroski J. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J. Virol. 2001, 75(7):3435-3443.
31. Korber B., Gaschen B., Yusim K., Thakallapally R., Kesmir C., Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 2001, 58:19-42.
32. Korber B., Gnanakaran S. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr. Opin. HIV AIDS 2009, 4(5):408-417.
33. Krachmarov C., Pinter A., Honnen W.J., Gorny M.K., Nyambi P.N., Zolla-Pazner S., Kayman S.C. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J. Virol. 2005, 79(2):780-790.
34. Krachmarov C.P., Honnen W.J., Kayman S.C., Gorny M.K., Zolla-Pazner S., Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J. Virol. 2006, 80(14):7127-7135.
35. Kunert R., Wolbank S., Stiegler G., Weik R., Katinger H. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res. Hum. Retroviruses 2004, 20(7):755-762.
36. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W., Robinson J., Van Ryk D., Wang L., Burton D.R., Freire E., Wyatt R., Sodroski J., Hendrickson W.A., Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420(6916):678-682.
37. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393(6686):648-659.
38. Laakso M.M., Lee F.H., Haggarty B., Agrawal C., Nolan K.M., Biscone M., Romano J., Jordan A.P., Leslie G.J., Meissner E.G., Su L., Hoxie J.A., Doms R.W. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 2007, 3(8):e117.
39. Li B., Decker J.M., Johnson R.W., Bibollet-Ruche F., Wei X., Mulenga J., Allen S., Hunter E., Hahn B.H., Shaw G.M., Blackwell J.L., Derdeyn C.A. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J. Virol. 2006, 80(11):5211-5218.
40. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79(16):10108-10125.
41. Li Y., Rey-Cuille M.A., Hu S.L. N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection. AIDS Res. Hum. Retroviruses 2001, 17(16):1473-1479.
42. Lynch R.M., Shen T., Gnanakaran S., Derdeyn C.A. Appreciating HIV type 1 diversity: subtype differences in Env. AIDS Res. Hum. Retroviruses 2009, 25(3):237-248.
43. Madani N., Schon A., Princiotto A.M., Lalonde J.M., Courter J.R., Soeta T., Ng D., Wang L., Brower E.T., Xiang S.H., Kwon Y.D., Huang C.C., Wyatt R., Kwong P.D., Freire E., Smith A.B., Sodroski J. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 2008, 16(11):1689-1701.
44. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., Montefiori D.C. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 2005, 79(16):10103-10107.
45. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
46. Moore J.P., McKeating J.A., Huang Y.X., Ashkenazi A., Ho D.D. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 1992, 66(1):235-243.
47. Moore J.P., McKeating J.A., Weiss R.A., Sattentau Q.J. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990, 250(4984):1139-1142.
48. Moore J.P., Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 1996, 70(3):1863-1872.
49. Moore J.P., Thali M., Jameson B.A., Vignaux F., Lewis G.K., Poon S.W., Charles M., Fung M.S., Sun B., Durda P.J., et al. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J. Virol. 1993, 67(8):4785-4796.
50. Moore P.L., Gray E.S., Choge I.A., Ranchobe N., Mlisana K., Abdool Karim S.S., Williamson C., Morris L. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 2008, 82(4):1860-1869.
51. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type. J. Virol. 1993, 67:6642-6647.
52. Nakamura G.R., Byrn R., Wilkes D.M., Fox J.A., Hobbs M.R., Hastings R., Wessling H.C., Norcross M.A., Fendly B.M., Berman P.W. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. J. Virol. 1993, 67(10):6179-6191.
53. O'Rourke S.M., Schweighardt B., Phung P., Fonseca D.P., Terry K., Wrin T., Sinangil F., Berman P.W. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J. Virol. 2010, 84(21):11200-11209.
54. O'Rourke S.M., Schweighardt B., Scott W.G., Wrin T., Fonseca D.P., Sinangil F., Berman P.W. Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. J. Virol. 2009, 83(15):7728-7738.
55. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 2004, 78(19):10724-10737.
56. Peters P.J., Bhattacharya J., Hibbitts S., Dittmar M.T., Simmons G., Bell J., Simmonds P., Clapham P.R. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J. Virol. 2004, 78(13):6915-6926.
57. Pinter A., Honnen W.J., He Y., Gorny M.K., Zolla-Pazner S., Kayman S.C. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 2004, 78(10):5205-5215.
58. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72(4):2855-2864.
59. Rademeyer C., Moore P.L., Taylor N., Martin D.P., Choge I.A., Gray E.S., Sheppard H.W., Gray C., Morris L., Williamson C. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 2007, 368(1):172-181.
60. Repik A., Clapham P.R. Plugging gp120s cavity. Structure 2008, 16(11):1603-1604.
61. Ringe R., Thakar M., Bhattacharya J. Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naive Indian patients with recent infection. Retrovirology 2010, 7(1):76.
62. Rong R., Bibollet-Ruche F., Mulenga J., Allen S., Blackwell J.L., Derdeyn C.A. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J. Virol. 2007, 81(3):1350-1359.
63. Rong R., Gnanakaran S., Decker J.M., Bibollet-Ruche F., Taylor J., Sfakianos J.N., Mokili J.L., Muldoon M., Mulenga J., Allen S., Hahn B.H., Shaw G.M., Blackwell J.L., Korber B.T., Hunter E., Derdeyn C.A. Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J. Virol. 2007, 81(11):5658-5668.
64. Rong R., Li B., Lynch R.M., Haaland R.E., Murphy M.K., Mulenga J., Allen S.A., Pinter A., Shaw G.M., Hunter E., Robinson J.E., Gnanakaran S., Derdeyn C.A. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 2009, 5(9):e1000594.
65. Sagar M., Wu X., Lee S., Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 2006, 80(19):9586-9598.
66. Sattentau Q.J., Moore J.P., Vignaux F., Traincard F., Poignard P. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 1993, 67:7383-7393.
67. Seaman M.S., Janes H., Hawkins N., Grandpre L.E., Devoy C., Giri A., Coffey R.T., Harris L., Wood B., Daniels M.G., Bhattacharya T., Lapedes A., Polonis V.R., McCutchan F.E., Gilbert P.B., Self S.G., Korber B.T., Montefiori D.C., Mascola J.R. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010, 84(3):1439-1452.
68. Shen X., Dennison S.M., Liu P., Gao F., Jaeger F., Montefiori D.C., Verkoczy L., Haynes B.F., Alam S.M., Tomaras G.D. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5972-5977.
69. Smith J.D., Bruce C.B., Featherstone A.S., Downing R.G., Biryahawaho B., Clegg J.C., Carswell J.W., Oram J.D. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 1994, 10(5):577-583.
70. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat. Med. 2009, 15(8):866-870.
71. Sullivan N., Sun Y., Binley J., Lee J., Barbas C.F., Parren P.W., Burton D.R., Sodroski J. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J. Virol. 1998, 72(8):6332-6338.
72. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 1996, 70(2):1100-1108.
73. Vogel T., Kurth R., Norley S. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J. Immunol. 1994, 153(4):1895-1904.
74. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 2010, 22:358-366.
75. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(5950):285-289.
76. Walker L.M., Simek M.D., Priddy F., Gach J.S., Wagner D., Zwick M.B., Phogat S.K., Poignard P., Burton D.R. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 2010, 6(8):e1001028.
77. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422(6929):307-312.
78. Wu X., Changela A., O'Dell S., Schmidt S.D., Pancera M., Yang Y., Zhang B., Gorny M.K., Phogat S., Robinson J.E., Stamatatos L., Zolla-Pazner S., Kwong P.D., Mascola J.R. Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. J. Virol. 2011, 85(9):4578-4585.
79. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., Longo N.S., McKee K., O'Dell S., Louder M.K., Wycuff D.L., Feng Y., Nason M., Doria-Rose N., Connors M., Kwong P.D., Roederer M., Wyatt R.T., Nabel G.J., Mascola J.R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(5993):856-861.
80. Wyatt R., Moore J., Accola M., Desjardin E., Robinson J., Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 1995, 69(9):5723-5733.
81. Wyatt R., Thali M., Tilley S., Pinter A., Posner M., Ho D., Robinson J., Sodroski J. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J. Virol. 1992, 66(12):6997-7004.
82. Xiang S.H., Finzi A., Pacheco B., Alexander K., Yuan W., Rizzuto C., Huang C.C., Kwong P.D., Sodroski J. A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. J. Virol. 2010, 84(7):3147-3161.
83. Zhang M., Foley B., Schultz A.K., Macke J.P., Bulla I., Stanke M., Morgenstern B., Korber B., Leitner T. The role of recombination in the emergence of a complex and dynamic HIV epidemic. Retrovirology 2010, 7:25.
84. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., Kwon Y.D., Scheid J.F., Shi W., Xu L., Yang Y., Zhu J., Nussenzweig M.C., Sodroski J., Shapiro L., Nabel G.J., Mascola J.R., Kwong P.D. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329(5993):811-817.
85. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 2004, 4(3):199-210.
86. Zolla-Pazner S., Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 2010, 10(7):527-535.